Novel formulations of a bruton's tyrosine kinase inhibitor

Described herein is the Brutons tyrosine kinase (Btk) inhibitor 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including novel pharmaceutical formulations thereof. Also disclosed are pharmaceutical compositions that include the Btk inhibitor, as well as methods of using the Btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. 本文描述了布鲁顿氏酪氨酸激酶(Btk)抑制剂1-((R)-3-(4-氨基-3-(4-苯氧基苯基)-1H-吡唑并[3,4-d]嘧啶-1-基)哌啶-1-基)丙-2-烯-1-酮，包括其新型药物制剂。本发明还公开了包含所述Btk抑制剂的药物组合物，以及使用所述Btk抑制剂单独地或与其他治疗剂组合用于治疗自身免疫疾病或病症、异种免疫疾病或病症、包括淋巴瘤的癌症以及炎性疾病或病症的方法。